RPL7A

Across TCGA pan-cancer cohorts, RPL7A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPL7A data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher RPL7A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL7A expression acts as an unfavorable survival marker.

KIRC, PRAD, and LUSC are the cancer types where RPL7A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.146	0.808	.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	II,III,IV	0.170	0.629	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RPL7A–KIRC (DFS)

Open the KIRC breakdown →